Cersosimo, Eugenio MDSchool of Medicine |
![]() |
In July 2001, I joined the Division of Diabetes, Department of Medicine in the capacity of Assistant Professor, and I was immediately (12 months later) promoted to the level of Associate Professor. My transfer from the State University of New York (SUNY) at Stony Brook to the University of Texas Health Science Center at San Antonio (UTHSCSA) was motivated primarily by the realization of co-investigators, peers and experts in the field of my exceptional academic and clinical accomplishments in the area of diabetes and metabolism. At that time, I was involved in a 5-year NIH-sponsored project addressing the topic of renal glucose metabolism and its potential usefulness in the treatment of diabetes. Upon transferring to the UTHSCSA, I also brought with me funds from the Juvenile Diabetes Research & Foundation to pursue a related project, dedicated to type 1 diabetes. All the equipment, critical material and supplies necessary to conduct these studies were transported to the Texas Diabetes Institute (TDI)Research Laboratory, where I established my new research program.
|
10/2015 - Present | Associate Professor - Graduate School and UTHSCSA Graduate School | UTHSCSA, Diabetes, Obesity, Molecular Physiology, San Antonio, TX |
3/2002 - Present | Associate Professor / Clinical and Associate Professor of Medicine | University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX |
Year | Degree | Discipline | Institution |
1994 | Clinical Fellowship | Endocrinology (awarded a R29 grant by National Institutes of Health) | Mayo Graduate School Rochester , MN |
1991 | Residency | Medicine (NA) | Mayo Graduate School Rochester , MN |
1987 | Postdoctoral Fellowship | Surgery and Endocrinology (NA) | Sloan Kettering Memorial New York , NV |
1985 | PhD | Physiology (NA) | Vanderbilt University Nashville , TN |
1975 | MD | Clinical Sciences (NA) | Universidade Federal Fluminense Rio de Janeiro, Brazil , Brazil |
Clinical Diabetes Research- Clinical research program on progression and pathophysiology of type 2 diabetes and related complications. Major emphasis on strategies that modify natural course of disease and prevent cardiovascular and renal disease. The latter includes lifestyle changes and pharmacological interventions |
Clinical Diabetes and Obesity Management- Fully trained and updated with special expertise on diagnosis and management of clinical diabetes, and on nutritional and metabolic disorders; Actively involved in development & implementation of preventive strategies for obesity and type 2 diabetes, in youth and adult patients Knowledgeable about standard therapy and novel technologies to treat and manage type 1 and type 2 diabetes and obesity, |
Clinical Pharmacology and Pathophysiology- 1. Investigation of new pharmacological pathways with potential for prevention and treatment of obesity, type 2 diabetes and cardio-metabolic complications; 2. Extensive basic research program on molecular mechanisms related to abnormalities associated with insulin resistance and inflammation in skeletal muscle, adipocytes, myocardial and vascular smooth muscle. |
Endocrinology Practice- Trained, Licensed and Board-Certified in Internal Medicine and Endocrinology, Diabetes and Metabolism; Proficiency in diagnosis and clinical management of endocrine and metabolic disorders, which includes complex and sophisticated dynamic stimulation and suppression endocrine testing, "insulin and pancreatic clamp" procedures, trans-cutaneous muscle & adipose tissue biopsy, thyroid aspiration biopsy, measurements of blood flow and substrate fluxes using arteriovenous catheterization, insertion of nasogastric & naso-jejunal tubing, venous occlusion plethysmography, and ultrasonography of carotid and various peripheral arteries. |
Fluent in Spanish Portuguese Italian and French- Fluent and proficient in many languages |
Date | Description | Institution | # Students |
10/2015 - Present | Clinical Research | ||
Direct supervision of clinical and research activities of medical resident at the Texas Diabetes Institute. Once a year, one medical resident chooses to accompany our research work. While in this teaching experience, we provide freedom to each Resident to learn general research techniques and to gets some involvement in ongoing research projects (due to time restrictions, only one to two months of their time is permitted). Most programs combine basic and clinical research experience, with emphasis on Molecular Physiology methodology, study designing, implementation of some basic cell biology techniques and laboratory training. These activities are full time and require my supervision 6-8 hours per day, during the one entire month per year. In addition, supervision and clinic experience with patients is provided to resident interested in sub-specialty training and fellowship program. One such case is Carolina Solis-Herrera, M.D., who was under my supervision in this particular category, and she took advantage of this opportunity as a resident. This has generated a few academic publications and she is now completing the UT Endocrinology Fellowship Training Program. | |||
6/2002 - Present | Visiting Graduate Students | UTHSCSA | |
6/2001 - Present | Medical Spupervision of Health Care Providers in the Outpatient Clinic | UTHSCSA | 5 students |
Once or twice a year, in conjuntion with the Texas Diabetes Institute Research program, we receive Pharmacy students and other health care providers for clinical and research observation. These take nearly 2-4 hours once or twice per month and occur in the TDI outpatient clinic and research facilities | |||
6/2001 - Present | Rotation Student Supervision | UTHSCSA | |
6/2001 - Present | Clinical Endocrinology | The University of Texas Health Science Center | |
Group discussion (10-12 students per session) of clinical vignettes and real patients on the general area of diabetes diagnosis and management. These occurred once yearly and lasted a period of two weeks (~10 days) with students rotating to different faculty every day. I usually spend 30 minutes preparing for theses case discussions and each lasted 2-3 hours. | |||
6/2001 - Present | Clinical Research | ||
Mentor to Estela Wajcberg, M.D.: post-graduate fellow worked during the years of 2001-2005 on project addressing vascular dysfunction in young and adult patients with diabetes and obese subjects. During her training, Dr. Wajcberg learned numerous techniques used to examine glucose kinetics with isotope dilution and arterio-venous differences. She also became proficient in vascular assessment utilizing tools such as ultrasonography and micro-circulatory evaluations of the skin. Her project focused primarily on determining the degree of abnormalities, if any, were detected in carotid and brachial arteries in response to vasodilatory stimuli in young and adult pre-diabetes subjects. These findings were then correlated with known altered glucose kinetics, which were documented simultaneously using isotope dilution techniques with trititated glucose. Dr. Wajcberg completed these studies, interpreted the data, and she was able to present the results in national and international meetings. She also managed to publish a few manuscripts using final findings. | |||
6/2001 - Present | Clinical Endocrinology | The University of Texas Health Science Center | |
Two lectures presented every year for the Second Year medical students on the topics of i) Hypoglycemia and ii) Glucose Homeostasis. It took me approximately one hour for the preparation, one hour for the presentation and 30-45 minutes for discussion of each topic. In addition, these lectures generated extensive discussions post-lecture via E-mail, and also face-to-face encounters with some students. |
Abstract |
Cersosimo E, Xu X, Upala S, Triplitt C, Musi N. Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation: PubMed; 2014 Aug. (Physiol Rep; vol. 2, no. 8). |
Journal Article |
Cersosimo E, Solis-Herrera C, Triplitt C. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients J Bras Nefrol 2014 Jan;36(1):80-92. |
Review Article |
Cersosimo E. Novel Agents for the Treatment of Type 2 Diabetes Diabetes Spectrum 2015 May;27(2):100-112. |
Eugenio Cersosimo, Carolina Solis-Herrera, Michael E. Trautmann, Jaret Malloy, Curtis L. Triplitt. Assessment of Pancreatic Beta-Cell Function: Review of Methods and Clinical Applications Current Diabetes Review, 2014 Dec;10(1). |
Cersosimo E. Renal glucose handling and the kidney as a target for anti-diabetic medication Current Trends in Endocrinology 2014 Mar;7:81-94. |
Federal |
|
Funding Agency | NIH |
Title | Durability of Initial Triple Therapy in Diabetes |
Status | Active |
Period | 1/2009 - 8/2018 |
Role | Co-Investigator |
Grant Detail | Extended for additional 3 years with anticipated date of completion on December 2017 Funding provided at the same level described for previous 5 years UTHSCSA, American Diabetes Association and Astra-Seneca Combined funding |
Funding Agency | NIDDK |
Title | Gradual Diabetes Treatment (GRADE) |
Status | Active |
Period | 6/2012 - 6/2018 |
Role | Consultant |
Grant Detail | NIH-sponsored prospective clinical trial looking for best combination agents in treatment of diabetes. Principal Investigator: Ralph DeFronzo,MD Co-Principal Investigator:Eugenio Cersosimo,MD PhD NIH/NIDDK (UO1 DK 098246-01) Total amount (5 years) = $1,794.660 NCT = 01794143 |
Private |
|
Funding Agency | Janssen Pharmaceuticals |
Title | Effect of Combined Incretin-Based Therapy Plus Canagliflozin On Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients |
Status | Active |
Period | 10/2015 - 9/2018 |
Role | Principal Investigator |
Grant Detail | Clinical evaluation of the combined effects of canagliflozin and liraglutide in the management of obese type 2 diabetes PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD Sponsored by Janssen Pharmaceuticals Total Amount = $1,852,632 (3 years) NCS = 02324842 |
Funding Agency | AstraZeneca Pharmaceutical |
Title | AstraZeneca Dapa-Saxa Study |
Status | Active |
Period | 10/2015 - 9/2018 |
Role | Principal Investigator |
Grant Detail | Clinical evaluation of the combination therapy of saxagliptin and dapagliflozin in uncontrolled diabetes PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD Sponsored by Astra-Zeneca Pharmaceutical Total Amount = 2,137,434 (3 years) NCT = 02613897 |
Funding Agency | American Diabetes Association |
Title | Preservation of beta-cell function in Pre-Diabetes |
Status | Active |
Period | 1/2014 - 6/2017 |
Role | Co-Investigator |
Grant Detail | Study examines potential agents capable of slowing progressive beta-cell deterioration in pre-diabetes individuals Principal Investigator - Ralph DeFronzo, MD Co-Investigator - Eugenio Cersosimo, MD PhD sponsored by the American Diabetes Association Total amount = $540,000 (3 years) NCS - not yet assigned |
Funding Agency | VeroScience |
Title | Effect of Cycloset on glycemic control in type 2 diabetic patients inadequately controlled on GLP-1 analogue |
Status | Active |
Period | 6/2014 - 6/2017 |
Role | Co-Principal Investigator |
Grant Detail | Randomized controlled trial to assess improvements in glucose control and in specific vascular surrogate markers using dynamic tests in uncontrolled type 2 diabetes ;patients receiving GLP-1 receptor analogue |